Allergen exposure chambers: implementation in clinical trials in allergen immunotherapy. Issue 1 (29th July 2020)

• Record Type: Journal Article
• Authors: Pfaar, O.; Zieglmayer, P.
• Is Part Of: Clinical and translational allergy. Volume 10:Issue 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-07-29
• Subjects: Allergen exposure chamber -- Allergic -- Clinical trials -- Allergen immunotherapy -- Phase II; Allergy -- Periodicals; Immunology -- Periodicals; Allergy and Immunology -- Periodicals; Hypersensitivity -- Periodicals; Immune System Phenomena -- Periodicals; 616.97005
• DOI: 10.1186/s13601-020-00336-9
• Languages: English
• ISSNs: 2045-7022

Abstract

Abstract: Allergen exposure chambers (AECs) have been developed for controlled allergen challenges of allergic patients mimicking natural exposure. As such, these facilities have been utilized e.g., for proof of concept, dose finding or the demonstration of onset of action and treatment effect sizes of antiallergic medication. Moreover, clinical effects of and immunological mechanisms in allergen immunotherapy (AIT) have been investigated in AECs. In Europe AIT products have to fulfill regulatory requirements for obtaining market authorization through Phase I to III clinical trials. Multiple Phase II (dose‐range‐finding or proof‐of‐concept) trials on AIT products have been performed in AECs. However, they are not accepted by regulatory bodies for pivotal (Phase III) trials and a more thorough technical and clinical validation is requested. Recently, a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI) has outlined unmet needs in further development of AECs. The following review aims to address some of these needs on the basis of recently published data in the first part, whereas the second part overviews published examples of most relevant Phase II trials in AIT performed in AEC facilities.